LANCE GRIFFIN: Open Payments
NPI 1700212198 · MISSOULA, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,017 in 51 payments from 12 companies in 2025. Trend: 2023 $472 · 2024 $516 · 2025 $1,017
Food & beverage: $1,017
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $199 |
| Madrigal Pharmaceuticals | 5 | $147 |
| Janssen Biotech, Inc. | 5 | $130 |
| Aimmune Therapeutics, Inc. | 4 | $72 |
| Lilly USA, LLC | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| Celltrion USA Inc. | 2 | $32 |
| ORPHALAN INC | 1 | $30 |
Products named: ENTYVIO, REZDIFFRA, TREMFYA, MAVYRET, VOWST, OMVOH, DUPIXENT, VIBERZI.
Industry payments across MT — which companies pay providers there.
